Neuroinflammation in Hypertension Study

The Role of Neuroinflammation in Hypertension.Minocycline for Resistant Hypertension: a Randomized Double Blind Placebo-Controlled Trial

To demonstrate that in patients with resistant hypertension oral treatment with minocycline via inhibition of central immune cell activation and inflammation results in reduced central sympathetic outflow and concomitant lowering of BP.

This is a randomized, double-blind, placebo controlled, parallel group design study aiming to compare the effects of minocycline 100mg twice daily vs matched placebo for 12 weeks on ambulatory BP and the parameters of sympathetic and immune activation

Inclusion Criteria:

• Aged: 45 -65 years
• Signed informed consent
• Clinical diagnosis of Resistant Hypertension
• Daytime systolic ambulatory BP >135mmHg.

Exclusion Criteria:• eGFR of <45 mL/min/1.73m2

• History of myocardial infarction (MI) or any cardiovascular event within 3 months of screening period, clinically significant AV conduction disturbances and/or arrhythmias,
• current of past history of heart failure (LVEF ≤40%)
• psychotropic agents, antidepressants and NSAIDS
• alcohol consumption of >3 standard drinks.
• known hypersensitivity or contraindication to minocycline or other tetracyclines.